Ipswich Investment Management Co. Inc. held its stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 30,329 shares of the biopharmaceutical company’s stock at the end of the second quarter. Ipswich Investment Management Co. Inc.’s holdings in Pfizer were worth $1,068,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. Stelac Advisory Services LLC acquired a new position in shares of Pfizer during the second quarter worth approximately $110,000. Catamount Wealth Management increased its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares in the last quarter. Commonwealth Financial Services LLC increased its position in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares in the last quarter. Stuart Chaussee & Associates Inc. increased its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares in the last quarter. Finally, Jag Capital Management LLC acquired a new position in shares of Pfizer during the second quarter worth approximately $202,000. 69.65% of the stock is owned by institutional investors.
Pfizer Inc. (NYSE:PFE) traded up 0.32% during midday trading on Friday, hitting $34.26. The stock had a trading volume of 12,937,101 shares. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The stock’s 50-day moving average is $34.68 and its 200-day moving average is $33.90. The company has a market cap of $207.81 billion, a P/E ratio of 30.37 and a beta of 0.87.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the company posted $0.56 earnings per share. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.50%. Pfizer’s dividend payout ratio is currently 95.24%.
A number of brokerages recently commented on PFE. Argus reissued a “buy” rating and issued a $39.00 price target on shares of Pfizer in a report on Sunday, August 28th. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price objective on the stock in a research note on Monday, June 27th. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Barclays PLC restated an “equal weight” rating and set a $34.00 price objective on shares of Pfizer in a research note on Tuesday, August 2nd. Finally, Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, July 20th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.